This site is intended for healthcare professionals
NICE has ruled that eltrombopag (Revolade) can be considered for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) within its marketing authorisation, following a review of its 2010 guidance.
To be eligible for treatment, the patient must either be refractory to standard active treatments and rescue therapies or have severe ITP and a high risk of bleeding that needs frequent course of rescue therapies.
The NICE recommendations are made on the proviso that the manufacturer provides eltrombopag with the discount agreed in the patient access scheme.
The antihaemorrhagic agent eltrombopag (Revolade) is...
The most up-to-date drug information at your fingertips.
Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.
Use our timeline to follow the latest coronavirus developments...
Inhaled budesonide is the first widely available, inexpensive...
Use our constantly updated shortages tracker to check...
People under 30 are to be offered alternatives to the...
Drugs
Conditions
News and resources
MIMS Hosted